Abstract
The tribunal in charge of regulating drug prices in Canada should more closely scrutinize the price of new drugs, rather than the annual price increases posted by manufacturers on already-marketed drugs. That message was delivered to the Patented Medicines Prices Review Board in response to a
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
